Disease · MONDO_0005233

non-small cell lung carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. non-small cell lung carcinoma. Diseases, record MONDO_0005233. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005233

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: non-small cell lung carcinoma; Open Targets
Open Targets ID: MONDO_0005233; Open Targets
Other names: NSCLC, NSCLC - non-small cell lung cancer, non-small cell cancer of lung, non-small cell cancer of the lung, non-small cell carcinoma of lung, non-small cell carcinoma of the lung, non-small cell lung cancer, non-small cell lung carcinoma (disease); Open Targets
Disease Ontology: DOID:3908; Disease Ontology
MeSH: D002289; MeSH
NCI Thesaurus: C2926; NCI Thesaurus
Orphanet: ORPHA:488201; Orphanet
Highest stage of its drugs: Approval, for 59 of its 1,066 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs1,066

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PEMETREXED	CHEMBL225072	Small molecule	Approval	EMA Human Drugs	647	633	630	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Approval	DailyMed and EMA Human Drugs	623	608	556	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Approval	DailyMed and EMA Human Drugs	503	481	479	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Approval	EMA Human Drugs	456	455	455	Drugs and targets
ERLOTINIB	CHEMBL553	Small molecule	Approval	EMA Human Drugs, PMDA and TTD	309	304	296	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Approval	TTD	295	293	290	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Approval	DailyMed and EMA Human Drugs	306	288	288	Drugs and targets
OSIMERTINIB	CHEMBL3353410	Small molecule	Approval	EMA Human Drugs and TTD	256	254	246	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	252	247	247	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Approval	EMA Human Drugs, FDA and PMDA	182	179	178	Drugs and targets

1 to 10 of 1,066

See all 1,066 drugs

Targets629

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EGFR	Epidermal growth factor receptor	58	Epidermal growth factor receptor erbB1 antagonist; Epidermal growth factor receptor erbB1 binding agent; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 negative allosteric modulator; Epidermal growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/1956	Drugs and targets
KDR	Vascular endothelial growth factor receptor	37	Vascular endothelial growth factor receptor 2 antagonist; Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3791	Drugs and targets
TUBB	Tubulin	34	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	34	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	34	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	34	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/347733	Drugs and targets
TUBB3	Tubulin	34	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/10381	Drugs and targets
TUBB4A	Tubulin	34	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/10382	Drugs and targets
TUBB4B	Tubulin	34	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/10383	Drugs and targets
TUBB6	Tubulin	34	Tubulin beta inhibitor; Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/84617	Drugs and targets

1 to 10 of 629

See all 629 targets

Trials4,857

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 104 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00949910	An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)	Phase 4	6,586	2016-10-04	Non-Small Cell Lung Cancer	ERLOTINIB	Its record names the disease	ClinicalTrials.gov
NCT05834348	A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.		5,279	2025-03-30	Non-Small Cell Lung Cancer	AFATINIB, ALECTINIB, ATEZOLIZUMAB, BEVACIZUMAB, BRIGATINIB, CARBOPLATIN, CERITINIB, CRIZOTINIB, DACOMITINIB, DOCETAXEL, ENTRECTINIB, ERLOTINIB, GEFITINIB, LORLATINIB, NIVOLUMAB, OSIMERTINIB, PACLITAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02474355	Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC	Phase 3	3,017	2021-10-25	Lung Cancer	OSIMERTINIB	Its record names the disease	ClinicalTrials.gov
NCT02477826	An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)	Phase 3	2,747	2025-10-30	Non-Small Cell Lung Cancer	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00858364	Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy	Phase 3	2,549	2018-07-06	Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer	DARBEPOETIN ALFA	Its record names the disease	ClinicalTrials.gov
NCT00480025	GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer	Phase 3	2,278	2019-01-30	Lung Cancer, Non-Small Cell	ASTUPROTIMUT-R	Its record names the disease	ClinicalTrials.gov
NCT01597258	Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)		2,029	2019-09-13	Non-small Cell Lung Cancer	CRIZOTINIB	Its record names the disease	ClinicalTrials.gov
NCT00148798	Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)	Phase 3	1,861	2011-10-04	Non Small Cell Lung Cancer (NSCLC)	CETUXIMAB, CISPLATIN, VINORELBINE	Its record names the disease	ClinicalTrials.gov
NCT01996332	A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)	Phase 2	1,805	2014-07-10	Non-Small Cell Lung Cancer	ERLOTINIB	Its record names the disease	ClinicalTrials.gov
NCT00312377	ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer	Phase 3	1,690	2011-05-24	Non-small Cell Lung Cancer, Lung Cancer	DOCETAXEL, VANDETANIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 4,857

See all 4,857 trials

Comparisons in its trials902

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Biomarker Cohort vs Non-biomarker Cohort: deaths from any cause	364 of 618	3,780 of 4,661	5,279	NCT05834348	Trial comparisons
Darbepoetin Alfa vs Placebo: deaths from any cause	1,273 of 1,685	657 of 833	2,518	NCT00858364	Trial comparisons
Darbepoetin Alfa vs Placebo: serious adverse events	524 of 1,685	259 of 833	2,518	NCT00858364	Trial comparisons
Darbepoetin Alfa vs Placebo: Number of Participants Who Developed Neutralizing Antibodies to Darbepoetin Alfa	0 of 1,606	0 of 803	2,409	NCT00858364	Trial comparisons
GSK1572932 Group vs Placebo Group: Number of Patients With Serious Adverse Events (SAEs) - Up to Data Lock Point (DLP)	330 of 1,515	164 of 757	2,272	NCT00480025	Trial comparisons
GSK1572932 Group vs Placebo Group: deaths from any cause	30 of 1,515	17 of 757	2,272	NCT00480025	Trial comparisons
GSK1572932 Group vs Placebo Group: serious adverse events	330 of 1,515	164 of 757	2,272	NCT00480025	Trial comparisons
Tecemotide (L-BLP25) + Cyclophosphamide vs Saline + Placebo: serious adverse events	303 of 1,024	151 of 477	1,501	NCT00409188	Trial comparisons
Arm I (Chemotherapy) vs Arm II (Chemotherapy, Bevacizumab): serious adverse events	424 of 738	563 of 735	1,473	NCT00324805	Trial comparisons
Vandetanib 100 mg Plus Docetaxel vs Placebo Plus Docetaxel: Objective Response Rate (ORR)	120 of 694	71 of 697	1,391	NCT00312377	Trial comparisons

1 to 10 of 902

See all 902 comparisons in its trials

Papers from its trials2,691

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41999747	RESULT	1	PubMed
41896648	RESULT	1	PubMed
41125109	RESULT	1	PubMed
40762544	RESULT	1	PubMed
40528044	RESULT	1	PubMed
40473109	RESULT	1	PubMed
40419140	RESULT	1	PubMed
40157574	RESULT	1	PubMed
40069402	RESULT	1	PubMed
40057343	RESULT	2	PubMed

1 to 10 of 2,691

See all 2,691 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005233

GET https://conductscience.org/api/diseases/v1/MONDO_0005233/drugs?page=2

API reference For AI assistants